[Assessment of dry body-weight in hemodialysis patients by plasma cyclic 3'5'-guanosine monophosphate].

OBJECTIVE

The aim of this paper was to investigate the changes in cyclic 3'5'-guanosine monophosphate (cGMP) before and after hemodialysis to estimate the value of cGMP to the dry boby-weight.

METHODS

Plasma cGMP levels (by radioimmunoassay), cardiothoracic ratio (CTR), and the body weight (BW) before and after hemodialysis were determined in chronic hemodialysis patients and clinical signs and symptoms were observed at the same time.

RESULTS

1. The predialytic cGMP value of the patients was significantly higher than that of healthy controls (P < 0.05). 2. The postdialytic cGMP level was significantly lower than the predialytic cGMP level (P < 0.01). 3. Postdialytic CTR and BW values were significantly lower than predialytic values (P < 0.01). 4. Compared to those of predialysis, postdialytic clinic signs and symptoms of the patients were significantly relieved.

CONCLUSIONS

1. The plasma cGMP level can sensitively reflect the hydration state and is a reliable marker for dry body-weight estimation. 2. The measurement of plasma cGMP combined with clinical parameters and radiological indexes permit a more accurate dry body-weight estimation.